David Bredt, Chief Scientific Officer at Rapport Therapeutics, Inc. (RAPP), sold 8,500 shares at $26.83 ($228K) on 2026-01-15, disclosed to the SEC on 2026-01-16.
Scheduled sale ($228k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.83 | 8,300 | $223K | 97.6% |
| 2 | $27.40 | 200 | $5K | 2.4% |
| Total | $26.84 avg | 8,500 | $228K | 100% |
| Filing → |
| RAPP | SELL | 2025-12-16 | $486K | — | Filing → |
| RAPP | SELL | 2025-11-18 | $428K | — | Filing → |
| RAPP | SELL | 2025-10-16 | $410K | — | Filing → |